In vivo pharmacokinetics

Pharmacokinetics characterises the rate and extent of drug absorption, the concentrations and time course of drug in the body, and the rate and mechanisms of elimination. This information allows the identification of features limiting the desired route of administration.

Coupled with results from in vitro ADME screens, in vivo PK data enables the early identification of compound liabilities. This provides a basis for structural modifications, or for the early development of strategies to overcome these problems.

Pharmacokinetic studies include the development of safe and tolerable formulations suitable for preclinical studies and we utilise an automated blood sampling system to reduced animal handling, provide overnight sampling, flexible study design and highly reproducible data..

We also offer a range of mechanistic studies to characterise individual processes that underpin the pharmacokinetic profile of drug candidates, including in vitro assessment of blood/plasma stability, binding to plasma proteins, distribution into red blood cells, or specialised in situ intestinal or hepatic perfusion models.

Research platforms include:

  • in vivo PK and bioavailability (rat/mouse)
  • dose dependency of PK and bioavailability
  • renal and biliary excretion
  • isolated perfused liver
  • portal vein and bile duct cannulation
  • BBB penetration (rat/mouse)
  • plasma protein binding
  • whole blood-to-plasma partitioning
  • stability in blood or plasma
  • stability in gastric and intestinal fluids